Renalytix AI
Penarth
About Renalytix AI
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, and patient stratification for drug clinical trials. RenalytixAI’s technology platform will draw from distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers, and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $88.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: lse:RENX
- Website: renalytix.com
- Phone: +44 (0)20 7933 8780
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/renalytix-ai-40467 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.